SenzaGen
SenzaGen signs distributor agreement with the Danish Technological Institute in Denmark (MFN)
SenzaGen has signed a distributor agreement with the reputable Danish Technological Institute (DTI). DTI holds a strong position as a proponent of new technology towards a large network of global customers, leading research institutes and universities. With this agreement SenzaGen further expand its licensing and distribution network in Europe with a strategically important partner.
The distributor agreement gives DTI the right to market and sell SenzaGen's test platform GARD® to both Danish and global customers in a wide range of industry sectors, including the chemical, pharmaceutical and medical technology industries, who want to increase the accuracy of their test results while avoiding animal studies. The agreement initially runs for 1 year with the possibility of extension.
“DTI holds a leading position in the life science industry in Denmark and the Nordic countries. With its unique position and competence, DTI helps to introduce, apply and disseminate new technology and knowledge into society. DTI has a strong presence in many of the industries that we prioritize, and together with DTI we look forward to introducing the GARD technology to their customers,” says Axel Sjöblad, CEO of SenzaGen.
DTI is an independent research and development institute that develops, applies and disseminates knowledge in the field of research and technology. With more than 10,000 customers in 65 countries and an annual turnover of approximately DKK 1 billion, DTI's experts support and participate in a large number of development projects in close collaboration with R&D establishments and universities around the world. In addition, DTI carries out consultancy services, training, certification, and safety testing in a variety of scientific fields, not the least of which is life sciences. By giving its customers access to the latest technology and knowledge, DTI encourages new innovative ideas and contributes to sustainable solutions.
The reliable GARD assay fits DTI’s mission by improving the quality of customers decision-making and contributing to increased product safety in people’s everyday lives.
“At DTI, we are protective of our position as a leading research institute and are therefore thorough in our selection and evaluation of the scientific methods we apply. With GARD® technology, we strengthen our offering in safety testing and biocompatibility testing with one of the industry's most reliable and accurate in vitro tests for skin and respiratory sensitization," says Sune Dowler Nygaard, Vice President, Life Science at DTI.
Contacts
Axel Sjöblad, CEO, SenzaGen AB
Email: axel.sjoblad@senzagen.com| Mobile: +46 705-35 93 51
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com| Mobile: +46 708-20 29 44
About us
About GARD
GARD™ consists of a group of tests for analysing a chemical’s capacity to trigger an allergic reaction in humans. The tests target companies looking to optimize their testing strategy and increase the accuracy of their test results while avoiding animal testing. With precision and reliability, GARD improves the quality of customers’ decision-making and contributes to increased product safety while reducing the number of animal tests. SenzaGen is the only company at this time that can provide an in vitro test to determine whether a chemical causes respiratory allergies. The Company’s product portfolio consists of tests for skin and respiratory allergies: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.
About SenzaGen AB (publ)
SenzaGen’s technology enables the replacement of animal testing with genetic testing in test tubes to determine the allergenicity of the chemicals we come in contact with in our everyday lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The Company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct and through partners. SenzaGen has its headquarters in Lund, Sweden, and a subsidiary in the US. For more information, please visit: www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser.